Masitinib
As of the edition of 20 October 2026, Masitinib is a small molecule: stopped in 2026; acts on FGFR3, KIT and PDGFRA and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 37, 6 stopped early
- Disease areas
- Immune system; Cancer; Nervous system; Skin and connective tissue; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 13 | 10 | 0 | 0 |
| Phase 3 | 23 | 12 | 3 | 6 |
| All trials | 37 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AB Science | Lead sponsor of trials | 2004 to now |